ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Purpose Estrogen receptor alpha (ER alpha) mediates the growth stimulation of estrogen in breast cancer cells and is a useful predictive factor for response to endocrine therapy. It is reported that ER alpha was induced in ER alpha negative breast cancer cells by both DNA methyltransferase-1 (DNMT1) inhibitor 5-aza-2'-deoxycytidine (AZA) and histone deacetylase (HDAC) inhibitor trichostatin A (TSA). However, whether the breast cancer cells with induced ER alpha restore response to endocrine therapy requires to be further researched.Patients and methods Reverse transcriptase-polymerase chain reaction (RT-PCR) method was used to explore the change in the mRNA of ER alpha, PR and pS2 in the ER alpha negative breast cancer cells MDA-MB-435 treated with two chemicals (AZA + TSA). Water-soluble tetrazolium salt-8 (WST-8) method was used to study the proliferation rate of the breast cancer cells. Flow cytometer (FCW) was used to analyze the distribution of cell cycle of these breast cancer cells. Some xenograft models in nude mice were used to further study the results we found in vitro.Results In this study we observed that the mRNA of ER alpha, PR and pS2 in the ER alpha negative breast cancer cells MDA-MB-435 was re-expressed by treatment with AZA + TSA. The proliferation assay analysis showed AZA + TSA suppressed the proliferation of MDA-MB-435 cells, which were further suppressed by addition of 4-OH Tamoxifen (4-OHT). On the contrary, the proliferation of cells treated with 4-OHT alone showed no difference compared with the vehicle control. Cell cycle analysis showed AZA + TSA treated cells showed S phase arrest, which was partially attenuated by addition of estradiol (E2); furthermore, the effect of E2 on stimulation of cell cycle could be reversed by 4-OHT in the treated cells with induced ER alpha. In vivo experiment xenograft volume of MDA-MB-435 cells treated with AZA + TSA was smaller than that of the control (P < 0.01), and the xenograft of AZA + TSA treated cells was further suppressed by ovariectomy (P < 0.01).Conclusions Our data indicate that DNMT1 inhibitor AZA and HDAC inhibitor TSA play important roles in restoring sensitivity of the ER alpha negative breast cancer cells to endocrine therapy in vitro and in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epigenetic modification alters gene expression leading to endocrine therapy resistance and may be reversed by epigenetic modifiers such as histone deacetylase (HDAC) inhibitors.6-8”
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648 · cited 1×
“These epigenetic modiWcations are post-transcriptional and reversible events, which do not interfere with or change the gene sequence or result in gene deletion (Baylin and Bestor 2002; Jones and Baylin 2002 ).”
BackgroundCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Haagenson, C. (1971) · Cited by 1,773
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157 · cited 1×
“Various HDAC inhibitors have been described to induce growth arrest, cell diVerentiation in vivo and in vitro (Munster et al. 2001; Marks et al. 2000 ).”
BackgroundShou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Number of CpG islands and genes in human and mouse.
Antequera, F., & Bird, A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11995 · Cited by 996 · cited 1×
“Several studies have shown that these epigenetic modiWcations could be manipulated pharmacologically by using DNA methyltransferase (DNMT) inhibitors such as 5-aza-2-deoxycytidine (AZA) and histone deacetylase (HDAC) inhibitors including trichostatin A (TSA) (Cheung et al. 2000; Antequera and Bird 1993; Zhu et al. 200…”
BackgroundButler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon‐Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2000) · PubMed · Cited by 615
Vigushin, D. M., Ali, S., Pace, P., Mirsaidi, N., Ito, K., Adcock, I. M., & Coombes, R. C. (2001) · PubMed · Cited by 447
Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., & Davidson, N. E. (2001) · PubMed · Cited by 430
Münster, P. N., Troso-Sandoval, T. A., Rosen, N. X., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2001) · PubMed · Cited by 402
Research works printed but not linked: 2
- Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D, Davidson NE (2003b) A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat 81(3):177–186 · DOI
- Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE (2001b) Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 61(19):7025–7029
Cited by
García-Becerra, R., Santos, N., Díaz, L., & Camacho, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms14010108 · Cited by 253
Rational Therapeutic Combinations with Histone Deacetylase Inhibitors for the Treatment of Cancer
Thurn, K. T., Thomas, S., Moore, A., & Munster, P. N. (2011) · Future Oncology · doi:10.2217/fon.11.2 · Cited by 246
SIRT1 Deacetylates the DNA Methyltransferase 1 (DNMT1) Protein and Alters Its Activities
Peng, L., Yuan, Z., Ling, H., Fukasawa, K., Robertson, K., Olashaw, N., Koomen, J., Chen, J., Lane, W. S., & Seto, E. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.06147-11 · Cited by 222
“To determine whether inhibition of SIRT1 activity affects repression of the ESR1 and CDH1 promoters, we treated MDA-MB-231 cells with TSA (which inhibits class I and II HDACs), nicotinamide (which inactivates all sirtuins), EX-527 (which selectively inhibits SIRT1 in low concentrations), or splitomicin (which inhibits…”
BackgroundInfluentialEndocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
Rani, A., Stebbing, J., Giamas, G., & Murphy, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00245 · Cited by 219
VIEDMA-RODRÍGUEZ, R., BAIZA-GUTMAN, L., SALAMANCA-GÓMEZ, F., DIAZ-ZARAGOZA, M., MARTÍNEZ-HERNÁNDEZ, G., ESPARZA-GARRIDO, R. R., VELÁZQUEZ-FLORES, M. A., & ARENAS-ARANDA, D. (2014) · Oncology Reports · doi:10.3892/or.2014.3190 · Cited by 182
“Co-treatment with inhibitors of DNA methyltransferase-1 (DNMT-1), such as 5-Aza-2-deoxycytidine (AZA), or inhibitors of histone deacetylase (HDAC), like trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), induce ER gene expression in ER(-) breast cancer cells and restore sensitivity to anti-estrogen (38,4…”
Background
Metadata
- Authors
- Fan, J., Yin, W.-J., Lu, J.-S., Wang, L., Wu, J., Wu, F.-Y., Di, G.-H., Shen, Z.-Z., & Shao, Z.-M.
- Affiliations
- Fudan University (CN)
- Corresponding author
- Shao, Zhi-Min
- Venue
- Journal of Cancer Research and Clinical Oncology
- Published
- 2008-02-09
- Volume
- 134
- Issue
- 8
- Pages
- 883-890
- ISSN
- 0084-5353 (ISSN-L)
- 0171-5216
- 1432-1335
- PMC
- PMC12160743
- OpenAlex
- W2055873602
- Cited by
- 129
- References
- 28
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 9 · 2020: 5 · 2019: 4 · 2018: 6 · 2017: 5 · 2016: 11 · 2015: 8 · 2014: 10 · 2013: 7 · 2012: 8
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Cancer Research and Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- cancer, estrogen receptor alpha, endocrine therapy resistance, decitabine, histone deacetylase inhibition, trichostatin A, combination therapy, tamoxifen, cell cycle arrest, MDA-MB-435 cells, xenograft tumor growth, ovariectomy, breast cancer
- MeSH terms
- Trefoil Factor-1, DNA (Cytosine-5-)-Methyltransferase 1, Decitabine, Animals, Azacitidine, Breast Neoplasms, DNA (Cytosine-5-)-Methyltransferases, Enzyme Inhibitors, Estradiol, Estrogen Antagonists, Estrogens, Female, Flow Cytometry, Humans, Hydroxamic Acids, Receptors, Progesterone, RNA, Messenger, Tamoxifen, Reverse Transcriptase Polymerase Chain Reaction, Xenograft Model Antitumor Assays, Tumor Suppressor Proteins, Cell Line, Tumor, Estrogen Receptor alpha, Cell Proliferation, Mice, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. https://app.cochat.ai/papers/10.1007/s00432-008-0354-x
- The paper
- Fan, J., Yin, W.-J., Lu, J.-S., Wang, L., Wu, J., Wu, F.-Y., Di, G.-H., Shen, Z.-Z., & Shao, Z.-M. (2008). ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-008-0354-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.